American Journal of Cancer

, Volume 3, Issue 6, pp 337–348

The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia

Current Opinion

Abstract

The Philadelphia chromosome and resultant Bcr-Abl fusion protein define most cases of chronic myelogenous leukemia (CML). The characterization of this protein and its integral role in the pathogenesis of leukemia has led to the development of specific inhibitors of Bcr-Abl which possess potent anti-tumor activity both in vitro and in vivo.

Imatinib, the only widely available Bcr-Abl inhibitor, represents the paradigm for rational drug development in the treatment of malignancies. It is highly effective in the treatment of chronic phase CML disease, producing a 95% complete hematologic response rate in interferon (IFN)-resistant patients. In contrast to IFN-based therapy, the majority of patients on imatinib will achieve a major cytogenetic response, suggesting a potential survival benefit. Imatinib also has a significantly more favorable toxicity profile than IFN or transplant-based strategies. Importantly, progression to the accelerated or blastic phases of the disease is rare in patients responding to imatinib.

On the basis of these findings, the majority of patients with chronic phase CML should be considered for a trial of therapy with imatinib, either in the clinic or in the context of a clinical trial. Failure to achieve a complete hematologic response within 3 months or a cytogenetic response within 6 months should lead to consideration of allogeneic transplantation, IFN therapy or participation in available clinical trials. While a substantial proportion of patients with accelerated or blastic phase disease will have a response to imatinib, these responses are transient with eventual resistance as the rule. Therefore, single-agent treatment with imatinib in this setting is not recommended unless it is used as a bridge to more definitive therapy such as transplantation.

References

  1. 1.
    Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001; 286(8): 895–8PubMedCrossRefGoogle Scholar
  2. 2.
    Sawyers CL. Medical progress: chronic myeloid leukemia. N Engl J Med 1999; 340(17): 1330–40PubMedCrossRefGoogle Scholar
  3. 3.
    Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341(3): 164–72PubMedCrossRefGoogle Scholar
  4. 4.
    Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94(1): 69–74PubMedCrossRefGoogle Scholar
  5. 5.
    Gribble SM, Sinclair PB, Grace C, et al. Comparative analysis of G-banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet 1999; 111(1): 7–17PubMedCrossRefGoogle Scholar
  6. 6.
    Talpaz M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314(17): 1065–9PubMedCrossRefGoogle Scholar
  7. 7.
    Colombat M, Chollet C, Fort M-P, et al. Decreasing Bcr-Abl level, in contrast to the Bcr-Abl load at the start of treatment, is significantly associated with cytogenetic response to imatinib in chronic myelogenous leukemia patients [abstract]. Blood 2002; 100(11): 319bGoogle Scholar
  8. 8.
    Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients ‘late,’ 18 months or more after transplantation. Blood 2001; 98(6): 1701–7PubMedCrossRefGoogle Scholar
  9. 9.
    Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Huntingt) 1999; 13(2): 169–80Google Scholar
  10. 10.
    Chronic Myeloid Leukemia Trialists’ Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89(21): 1616–20CrossRefGoogle Scholar
  11. 11.
    Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17Suppl. 3: S5–6PubMedGoogle Scholar
  12. 12.
    Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63(4): 789–99PubMedGoogle Scholar
  13. 13.
    Kantarjian HM, Keating MJ, Smith TL, et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990; 88(1): 1–8PubMedCrossRefGoogle Scholar
  14. 14.
    Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90(11): 850–8PubMedCrossRefGoogle Scholar
  15. 15.
    Kantarjian HM, Giles FJ, O’Brien SM, et al. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998; 12(1): 31–80PubMedCrossRefGoogle Scholar
  16. 16.
    Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea: the German CML Study Group. Blood 1993; 82(2): 398–407PubMedGoogle Scholar
  17. 17.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia.Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Am J Clin Pathol 2000; 114(1): 57–65PubMedCrossRefGoogle Scholar
  18. 18.
    Fefer A, Cheever MA, Thomas ED, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979; 300(7): 333–7PubMedCrossRefGoogle Scholar
  19. 19.
    Clift RA, Buckner CD, Thomas ED, et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; II(8299): 621–3CrossRefGoogle Scholar
  20. 20.
    Clift RA, Starb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17Suppl. 3: S1–3PubMedGoogle Scholar
  21. 21.
    Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia: Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17Suppl. 3: S7–9PubMedGoogle Scholar
  22. 22.
    van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20(7): 553–60PubMedCrossRefGoogle Scholar
  23. 23.
    Brinch L, Egeland T, Tjoennfjord G, et al. Allogeneic stem cell transplantation for CML: a single center experience with 125 patients [abstract]. Blood 2002; 100(11): 428aGoogle Scholar
  24. 24.
    Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94(5): 1517–36PubMedGoogle Scholar
  25. 25.
    Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001; 115(3): 569–74PubMedCrossRefGoogle Scholar
  26. 26.
    Copelan E, Crilley P, Kalaycio M, et al. Is delay in transplantation of older individuals with cml a scif-fulfilling prophecy [abstract]? The 44th annual meeting of the American Society of Hematology; 2002 Dec 6–10; Philadelphia (PA)Google Scholar
  27. 27.
    Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352(9134): 1087–92PubMedCrossRefGoogle Scholar
  28. 28.
    Ozer H, George S, Schiffer C, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood 1993; 82(10): 2975–84PubMedGoogle Scholar
  29. 29.
    Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy: the Leukemia Service. Ann Intern Med 1995; 122(4): 254–61PubMedGoogle Scholar
  30. 30.
    Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response: the UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345(8962): 1392–7PubMedCrossRefGoogle Scholar
  31. 31.
    Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98(10): 3074–81PubMedCrossRefGoogle Scholar
  32. 32.
    Chronic Myeloid Leukemia Trialists’ Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89(21): 1616–20CrossRefGoogle Scholar
  33. 33.
    Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months’ experience. Blood 2002; 100(2): 435–41PubMedCrossRefGoogle Scholar
  34. 34.
    Talpaz M, Kurzrock R, O’Brien S, et al. Unmaintained complete remissions (cures?) among interferon treated Philadelphia positive chronic myelogenous leukemia (CML PHI) patients [abstract]. Blood 1998; 92(10 Suppl. 1): 317aGoogle Scholar
  35. 35.
    Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia: French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337(4): 223–9PubMedCrossRefGoogle Scholar
  36. 36.
    Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99(5): 1527–35PubMedCrossRefGoogle Scholar
  37. 37.
    O’Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 2002; 94(7): 2024–32PubMedCrossRefGoogle Scholar
  38. 38.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a sciective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5): 561–6PubMedCrossRefGoogle Scholar
  39. 39.
    von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359(9305): 487–91CrossRefGoogle Scholar
  40. 40.
    Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346(9): 683–93PubMedCrossRefGoogle Scholar
  41. 41.
    Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia [letter]. Science 1960; 132: 1497Google Scholar
  42. 42.
    Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315(6020): 550–4PubMedCrossRefGoogle Scholar
  43. 43.
    Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306(17): 277–80PubMedCrossRefGoogle Scholar
  44. 44.
    Vigneri P, Wang JYJ. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7(2): 228–34PubMedCrossRefGoogle Scholar
  45. 45.
    Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96(6): 2269–76PubMedGoogle Scholar
  46. 46.
    Bhatia R, Verfaillie CM. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta 1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998; 91(9): 3414–22PubMedGoogle Scholar
  47. 47.
    Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98(6): 1732–8PubMedCrossRefGoogle Scholar
  48. 48.
    Huntly BJP, Bench AJ, Delabesse E, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002; 99(12): 4547–53PubMedCrossRefGoogle Scholar
  49. 49.
    Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t (9; 22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95(3): 738–43PubMedGoogle Scholar
  50. 50.
    Voncken JW, Kaartinen V, Pattengale PK, et al. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995; 86(12): 4603–11PubMedGoogle Scholar
  51. 51.
    Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and plateletderived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 139–45PubMedGoogle Scholar
  52. 52.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–7PubMedCrossRefGoogle Scholar
  53. 53.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038–42PubMedCrossRefGoogle Scholar
  54. 54.
    Sun G, Boczkowska B, Tcheurekdjian L. The emergence of cytogenetically unrelated clones may not be an uncommon finding in imatinib mesylate-treated CML [abstract]. Blood 2002; 100(11): 326bGoogle Scholar
  55. 55.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645–52PubMedCrossRefGoogle Scholar
  56. 56.
    Kantarjian H, Cortes J, O’Brien S, et al. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400mg or 800mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase [abstract]. Proceedings of the 38th annual meeting of ASCO; 2002 May 18–21; Orlando (FL)Google Scholar
  57. 57.
    Kantarjian HM, Cortes JE, O’Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101(1): 97–100PubMedCrossRefGoogle Scholar
  58. 58.
    Druker BJ. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study [abstract]. Proc Am Soc Clin Oncol 2002; 21: laGoogle Scholar
  59. 59.
    Larson RA. Imatinib (STI-571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia: results of a randomized phase III study vs interferon alpha + cytarabine [abstract]. Blood 2002; 100(11): 4aGoogle Scholar
  60. 60.
    O’Brien S, Vallance S, Craddock C, et al. PEGintron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukemia [abstract]. Blood 2001; 98: 846aGoogle Scholar
  61. 61.
    Gardembas M, Roussciot P, Tulliez M, et al. Imatinib (Gleevec) and cytarabine (Ara-C) is an effective regimen in Philadelphia positive chronic myelogenous leukemia chronic phase patients [abstract]. Blood 2002; 100(11): 95aGoogle Scholar
  62. 62.
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928–37PubMedCrossRefGoogle Scholar
  63. 63.
    Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myeloid leukemia. Cancer 1988; 61(7): 1441–6PubMedCrossRefGoogle Scholar
  64. 64.
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530–9PubMedCrossRefGoogle Scholar
  65. 65.
    Sacchi S, Kantarjian HM, O’Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86(12): 2632–41PubMedCrossRefGoogle Scholar
  66. 66.
    Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99(10): 3547–53PubMedCrossRefGoogle Scholar
  67. 67.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL typrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–7PubMedCrossRefGoogle Scholar
  68. 68.
    Cortes J, Talpaz M, Giles FJ, et al. High-dose imatinib mesylate (STI571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon alpha (IFN) [abstract]. Proceedings of the 38th annual meeting of ASCO; 2002 May 18–21; Orlando (FL)Google Scholar
  69. 69.
    Shah N, Nicoll JM, Wang J, et al. Molecular monitoring of chronic myelogenous leukemia patients with sustained cytogenetic remissions in response to imatinib: quantitative RT-PCR reveals a wide range of persistent Bcr-Abl transcript levels in the majority of patients [abstract]. The 44th annual meeting of the American Society of Hematology; 2002 Dec 6–10; Philadelphia (PA)Google Scholar
  70. 70.
    Hughes T, Kaeda J, Branford S, et al. Molecular responses to imatinib or interferen + Ara-C as initial therapy for CML; results of the IRIS study [abstract]. The 44th annual meeting of the American Society of Hematology; 2002 Dec 6–10; Philadelphia (PA)Google Scholar
  71. 71.
    Cortes J, Talpaz M, Giles F, et al. High-dose imatinib mesylate in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN) induces molecular remissions [abstract]. Blood 2002; 100(11): 164aGoogle Scholar
  72. 72.
    Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293(5538): 2163PubMedCrossRefGoogle Scholar
  73. 73.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876–80PubMedCrossRefGoogle Scholar
  74. 74.
    Barthe C, Cony-Makhoul P, Melo JV, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293(5538): 2163PubMedCrossRefGoogle Scholar
  75. 75.
    le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95(5): 1758–66PubMedGoogle Scholar
  76. 76.
    Mahon FX, Delninger MWN, Schulthels B, et al. selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96(3): 1070–9PubMedGoogle Scholar
  77. 77.
    Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alphal acid glycoproteln in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92(20): 1641–50PubMedCrossRefGoogle Scholar
  78. 78.
    Hofmann W-K, Vos SD, Elashoff D, et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002; 359(9305): 481–6PubMedCrossRefGoogle Scholar
  79. 79.
    La Rosee P, Johnson K, O’Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30(7): 729–37PubMedCrossRefGoogle Scholar
  80. 80.
    Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97(7): 1999–2007PubMedCrossRefGoogle Scholar
  81. 81.
    Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96(9): 3195–9PubMedGoogle Scholar
  82. 82.
    Tipping AJ, Mahon FX, Zafirides G, et al. Drug responses of imatinib mesylateresistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16(12): 2349–57PubMedCrossRefGoogle Scholar
  83. 83.
    Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15(3): 342–7PubMedCrossRefGoogle Scholar
  84. 84.
    Mauro MJ, O’Dwyer ME, Stone R, et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML [abstract]. Blood 2002; 100(11): 165aGoogle Scholar
  85. 85.
    Cortes J, Talpaz M, O’Brien S, et al. Significance of lack of early cytogenetic response after therapy with imatinib mesylate in relation to later achievement of major or complete cytogenetic response in patients with Philadelphia chromosome positive chronic myeloid leukemia [abstract]. The 44th annual meeting of the American Society of Hematology; 2002 Dec 6–10; Philadelphia (PA)Google Scholar
  86. 86.
    Hahn E, Sorensen M, Hudgens S, et al. Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus Ara-C vs imatinib [abstract]. Blood 2002; 100(11): 94aGoogle Scholar
  87. 87.
    Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogenelc stem cell transplantation. Blood 2002; 99(10): 3861–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Dax Kurbegov
    • 1
  • Hagop M. Kantarjian
    • 1
  • Moshe Talpaz
    • 1
    • 2
  1. 1.M.D. Anderson Cancer CenterThe University of TexasHoustonUSA
  2. 2.Department of Experimental TherapeuticsMD Anderson Cancer CenterHoustonUSA

Personalised recommendations